JP2010502717A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502717A5
JP2010502717A5 JP2009527438A JP2009527438A JP2010502717A5 JP 2010502717 A5 JP2010502717 A5 JP 2010502717A5 JP 2009527438 A JP2009527438 A JP 2009527438A JP 2009527438 A JP2009527438 A JP 2009527438A JP 2010502717 A5 JP2010502717 A5 JP 2010502717A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
compound according
compound
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502717A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/019588 external-priority patent/WO2008030584A2/en
Publication of JP2010502717A publication Critical patent/JP2010502717A/ja
Publication of JP2010502717A5 publication Critical patent/JP2010502717A5/ja
Pending legal-status Critical Current

Links

JP2009527438A 2006-09-07 2007-09-07 インターロイキン1受容体関連キナーゼの調節物質 Pending JP2010502717A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84280106P 2006-09-07 2006-09-07
PCT/US2007/019588 WO2008030584A2 (en) 2006-09-07 2007-09-07 Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase

Publications (2)

Publication Number Publication Date
JP2010502717A JP2010502717A (ja) 2010-01-28
JP2010502717A5 true JP2010502717A5 (cg-RX-API-DMAC7.html) 2011-01-20

Family

ID=39157878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527438A Pending JP2010502717A (ja) 2006-09-07 2007-09-07 インターロイキン1受容体関連キナーゼの調節物質

Country Status (15)

Country Link
US (1) US8293923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2061786A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010502717A (cg-RX-API-DMAC7.html)
KR (1) KR20090049076A (cg-RX-API-DMAC7.html)
CN (1) CN101616910A (cg-RX-API-DMAC7.html)
AU (1) AU2007292929A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663100A1 (cg-RX-API-DMAC7.html)
IL (1) IL197274A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009002377A (cg-RX-API-DMAC7.html)
NO (1) NO20091326L (cg-RX-API-DMAC7.html)
NZ (1) NZ575410A (cg-RX-API-DMAC7.html)
RU (1) RU2459821C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008030584A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901529B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2243481A1 (en) * 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
RU2632900C2 (ru) * 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
US9598440B2 (en) 2012-10-08 2017-03-21 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
JP6483624B2 (ja) * 2013-02-07 2019-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピリダジノン−アミド誘導体
ES2639717T3 (es) * 2013-02-07 2017-10-30 Merck Patent Gmbh Derivados de piridazinona macrocíclicos
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
SI3448848T1 (sl) 2016-04-29 2024-01-31 Bayer Pharma Aktiengesellschaft Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
SI3464266T1 (sl) 2016-06-01 2021-12-31 Bayer Animal Health Gmbh Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
CN106222183B (zh) * 2016-07-25 2019-11-08 南通大学 靶向人irak1基因的小干扰rna及其应用
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
AU2018350683A1 (en) 2017-10-19 2020-04-02 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
EP4410377A3 (en) 2017-10-31 2024-11-13 Curis, Inc. Compounds and compositions for treating hematological disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN114585609B (zh) * 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3214747A1 (en) 2021-04-08 2022-10-13 Reinhard Von Roemeling Combination therapies for the treatment of cancer
CN115710253B (zh) * 2021-08-23 2024-07-02 上海交通大学 一类含有氨基苯并咪唑类衍生物及其制备和用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716111D0 (en) * 1987-07-08 1987-08-12 Unilever Plc Edible plastic dispersion
HUP0000189A3 (en) * 1996-11-15 2002-01-28 Darwin Discovery Ltd Milton Ro Bicyclic aryl carboxamides pharmaceutical compositions containing them and their therapeutic use
JP2001518094A (ja) * 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Hivプロテアーゼ阻害剤として有用なインダゾール−環式尿素
HK1047582B (zh) * 1999-06-23 2005-03-04 萨诺费-阿文蒂斯德国有限公司 取代的苯並咪唑
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.

Similar Documents

Publication Publication Date Title
RU2009112598A (ru) Модуляторы киназы, ассоциированной с рецептором интерлейкина-1
JP5529827B2 (ja) TNFαシグナル伝達のモジュレータ
JP2012523457A5 (cg-RX-API-DMAC7.html)
JP2012522056A5 (cg-RX-API-DMAC7.html)
JP5468578B2 (ja) インテグリンのその受容体への結合を阻害するプロパン酸誘導体
ES2381589T3 (es) Aminometil-4-imidazoles
JP2007524696A5 (cg-RX-API-DMAC7.html)
JP2011503068A5 (cg-RX-API-DMAC7.html)
JP2022550099A5 (cg-RX-API-DMAC7.html)
RU2004117545A (ru) Аминопиримидины и пиридины
SK83594A3 (en) Imidazole derivatives, method of their preparation, their use for production of pharmaceutical compositions with their contents
KR20070107075A (ko) Cxcr3 길항제 활성을 갖는 신규의 헤테로사이클릭치환된 피리딘 또는 페닐 화합물
IL160522A (en) 1h - imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity
JP2012528166A5 (cg-RX-API-DMAC7.html)
KR101706486B1 (ko) 우울증, 당뇨병 및 파킨슨병과 같은 몇가지 장애의 치료에 사용하기 위한 taar 조절제로서의 피라졸 카복스아마이드 유도체
EP2240453A1 (en) Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
Rani et al. Trisubstituted imidazole synthesis: A review
JP2007530570A5 (cg-RX-API-DMAC7.html)
JP2011507868A5 (cg-RX-API-DMAC7.html)
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
HUP0303038A2 (hu) Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2007532654A5 (cg-RX-API-DMAC7.html)
JPWO1994002472A1 (ja) チアゾリン誘導体
Shrivastava et al. Divers pharmacological significance of imidazole derivatives-A review
EP1628968B1 (en) 4-imidazolin-2-one compounds